ANSWER: E

Rationale:

The stem "-afil" designates phosphodiesterase type 5 (PDE5) inhibitors, not glucagon-like peptide-1 (GLP-1) receptor agonists. Examples include sildenafil, tadalafil, and vardenafil, all used for erectile dysfunction and/or pulmonary arterial hypertension. GLP-1 receptor agonists carry the stem "-glutide" (e.g., semaglutide, liraglutide, dulaglutide). All other pairings in this question are correct: "-olol" correctly identifies beta-blockers (metoprolol, atenolol, propranolol); "-pril" correctly identifies ACE inhibitors (lisinopril, ramipril, enalapril); "-gliptin" correctly identifies DPP-4 inhibitors (sitagliptin, saxagliptin, alogliptin); and "-lukast" correctly identifies leukotriene receptor antagonists (montelukast, zafirlukast). Mastery of INN stems allows rapid class identification at the point of prescribing, pharmacovigilance reporting, and formulary management. QUESTION 2 A hospital pharmacist is asked to verify whether two drugs prescribed concurrently belong to the same pharmacological class. Drug X is described in its prescribing information as "a recombinant humanized monoclonal antibody targeting the PD-1 receptor." Drug Y is described as "a low-molecular-weight synthetic molecule that competitively inhibits the JAK1/JAK2 kinase domain." Which of the following best characterizes the drug source classification of Drug X and Drug Y, respectively? A) Drug X: semisynthetic biologic; Drug Y: natural product B) Drug X: biologic (large molecule); Drug Y: synthetic small molecule C) Drug X: synthetic small molecule; Drug Y: semisynthetic derivative D) Drug X: natural product; Drug Y: biologic E) Drug X: biologic (large molecule); Drug Y: semisynthetic derivative

ANSWER: B

Rationale:

Drug X is a recombinant humanized monoclonal antibody — a prototypical biologic (large molecule) produced by recombinant DNA technology in mammalian cell expression systems. Monoclonal antibodies targeting PD-1 (programmed death-1) include pembrolizumab and nivolumab, which are immune checkpoint inhibitors. Biologics are distinguished by their large molecular weight, protein-based structure, parenteral route of administration, and complex manufacturing requirements. Drug Y is described as a low-molecular-weight synthetic molecule — the defining characteristics of a synthetic small molecule drug. JAK1/JAK2 inhibitors such as ruxolitinib and baricitinib are synthesized entirely by chemical processes without biological expression systems. Option A is incorrect — "semisynthetic biologic" is not a standard source classification, and Drug Y is not a natural product. Option C reverses the classifications entirely. Option D is incorrect — monoclonal antibodies are not natural products; they are recombinant biologics. Option E is incorrect — Drug Y is a synthetic small molecule, not a semisynthetic derivative. QUESTION 3 A clinician is reviewing the Anatomical Therapeutic Chemical (ATC) classification for drugs used in a hospital formulary audit. She notes that two drugs share the same first three levels of the ATC code (e.g., C10A) but differ at the fourth and fifth levels. Which of the following conclusions is most pharmacologically justified? A) The two drugs have identical mechanisms of action and are fully interchangeable B) The two drugs belong to the same anatomical main group and broad therapeutic category but differ in their specific pharmacological subgroup or chemical entity C) The two drugs are manufactured by the same company and share patent protection D) The two drugs are bioequivalent and can be substituted without clinical adjustment E) The two drugs share the same route of administration as defined by the ATC fifth level

ANSWER: B

Rationale:

The ATC classification system is hierarchical across five levels: (1) anatomical main group (letter), (2) therapeutic main group (two-digit number), (3) therapeutic/pharmacological subgroup (letter), (4) chemical/pharmacological subgroup (two-digit number), (5) chemical substance (two-digit number). Two drugs sharing the first three levels (e.g., C10A) belong to the same anatomical group (C = cardiovascular), therapeutic main group (C10 = lipid-modifying agents), and pharmacological subgroup (C10A = lipid-modifying agents, plain), but diverge at the fourth level where specific mechanism class is encoded, and the fifth level where the individual chemical entity is identified. This means they are therapeutically related but not identical in mechanism or chemical structure. Option A is incorrect — shared upper ATC levels do not imply identical mechanism or interchangeability. Option C is incorrect — the ATC system has no relationship to patent or manufacturer status. Option D is incorrect — bioequivalence is a regulatory determination unrelated to ATC coding. Option E is incorrect — route of administration is not encoded within the standard five-level ATC code. QUESTION 4 Which of the following pairings of historical pharmacologist and their primary conceptual contribution is INCORRECT? A) John Newport Langley — postulated the existence of "receptive substances" on cell surfaces that mediate the action of drugs and neurotransmitters B) Paul Ehrlich — introduced the concept of selective toxicity and developed the first synthetic antimicrobial agent targeting Treponema pallidum C) Raymond Ahlquist — demonstrated that adrenergic responses arise from two receptor subtypes (alpha and beta) based on differential agonist potency ranking D) James Black — developed the first clinically useful beta-adrenoceptor antagonist and later the first H2-receptor antagonist, earning the Nobel Prize in Physiology or Medicine E) Rudolf Buchheim — proposed the receptor occupancy theory mathematically relating drug concentration to biological response

ANSWER: E

Rationale:

Rudolf Buchheim is recognized as the founder of experimental pharmacology as an academic discipline — he established the first university pharmacology laboratory in Dorpat (now Tartu, Estonia) in 1847 and emphasized the importance of experimental methods in studying drug action. He did not, however, formulate the receptor occupancy theory. That theory was developed by A.J. Clark in the 1920s–1930s, who applied the law of mass action to drug-receptor binding and derived the mathematical relationship between drug concentration and biological response. Option A is correct — Langley's studies on the effects of nicotine and curare on skeletal muscle led him to propose "receptive substances" at the neuromuscular junction, a foundational precursor to modern receptor theory. Option B is correct — Ehrlich's concept of selective toxicity and development of arsphenamine (Salvarsan) are accurately described. Option C is correct — Ahlquist's 1948 publication established the alpha/beta adrenoceptor classification. Option D is correct — James Black developed propranolol (beta-blocker) and cimetidine (H2 antagonist) and received the 1988 Nobel Prize in Physiology or Medicine. QUESTION 5 A physician is prescribing a new medication for a patient with type 2 diabetes and chronic kidney disease. Before finalizing the prescription, she defines the patient's problem, specifies her therapeutic objective, confirms there are no contraindications in this patient's specific context, counsels the patient on administration and expected side effects, and plans a follow-up visit to assess response and renal tolerability. This prescribing behavior is best described as an application of which of the following? A) Pharmacovigilance — systematic post-marketing surveillance of drug safety signals B) Therapeutic drug monitoring — using drug plasma levels to guide dosing decisions C) The WHO rational prescribing framework — a structured, patient-centered approach to drug selection and monitoring D) Formulary restriction — limiting prescribing choices to institutionally approved agents E) Pharmacoeconomic analysis — selecting therapy based on cost-effectiveness modeling

ANSWER: C

Rationale:

The behavior described maps directly onto the WHO six-step rational prescribing process: (1) define the patient's problem (type 2 diabetes with CKD), (2) specify the therapeutic objective (glycemic control without worsening renal function), (3) verify suitability for this patient (check for contraindications in CKD context), (4) start treatment, (5) provide information and instructions (counsel on administration and side effects), (6) monitor and stop if necessary (planned follow-up to assess renal tolerability and response). Rational prescribing is explicitly patient-individualized and distinguishes itself from protocol adherence alone by requiring integration of the patient's specific clinical context. Option A is incorrect — pharmacovigilance refers to systematic population-level monitoring of drug safety after market approval, not individual prescribing decisions. Option B is incorrect — therapeutic drug monitoring involves measuring plasma drug concentrations to guide dosing, which is not described here. Option D is incorrect — formulary restriction is an institutional administrative process, not a prescribing methodology. Option E is incorrect — pharmacoeconomic analysis involves formal cost-effectiveness or cost-utility modeling, not the clinical decision-making process described. This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.